Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by MBM Wealth Consultants LLC

MBM Wealth Consultants LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,664 shares of the pharmaceutical company’s stock after acquiring an additional 124 shares during the period. MBM Wealth Consultants LLC’s holdings in Vertex Pharmaceuticals were worth $1,081,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $25,000. Highline Wealth Partners LLC bought a new stake in Vertex Pharmaceuticals in the third quarter valued at about $27,000. Dunhill Financial LLC raised its stake in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares in the last quarter. Legacy Investment Solutions LLC bought a new position in Vertex Pharmaceuticals during the 3rd quarter worth approximately $33,000. Finally, Truvestments Capital LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $35,000. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

VRTX has been the topic of several research analyst reports. Bank of America reduced their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research note on Thursday, December 19th. Morgan Stanley raised their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Wells Fargo & Company lowered their price objective on shares of Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. HC Wainwright cut their target price on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a report on Friday, December 20th. Finally, UBS Group upped their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $490.38.

Vertex Pharmaceuticals Trading Up 1.4 %

VRTX stock opened at $427.89 on Wednesday. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $439.34 and a two-hundred day moving average of $465.72.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same quarter last year, the firm earned $3.67 earnings per share. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.